Vnitr Lek 2005, 51(5):497-498

Genetické testy v predikci toxicity chemoterapie - první krok nové éry onkoterapie - editorial

M. Svoboda
Laboratoř prediktivní onkologie Masarykova onkologického ústavu, Brno, ředitel prof. MUDr. Rostislav Vyzula, CSc.

Received: March 18, 2005; Published: May 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Svoboda M. Genetické testy v predikci toxicity chemoterapie - první krok nové éry onkoterapie - editorial. Vnitr Lek. 2005;51(5):497-498.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J 2004; 18: 790-804. Go to original source... Go to PubMed...
    2. Sanchez-Borges M, Capriles-Hulett A, Caballero-Fonseca F. Cutaneous reactions to aspirin and nonsteroidal antiinflammatory drugs. Clin Rev Allergy Immunol 2003; 24: 125-136. Go to original source... Go to PubMed...
    3. Cox GJ, Robertson DB. Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy. Arch Dermatol 1986; 122: 1413-1414. Go to original source... Go to PubMed...
    4. Weber WW. Pharmacogenetic tactics and strategies: implications for paediatrics. Paediatr Drugs 2001; 3: 863-881. Go to original source... Go to PubMed...
    5. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 1999; 59: 1391-1319.
    6. Lee W, Lockhart AC, Kim RB et al. Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 2005; 10: 104-111. Go to original source... Go to PubMed...
    7. Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med 2005; 352: 476-487. Go to original source... Go to PubMed...
    8. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non-Small-Cell Lung Cancer. J Clin Oncol 2005; www.jco.org. Go to original source... Go to PubMed...
    9. Rajkumar SV, Richardson PG, Hideshima T et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 2005; 23: 630-639. Go to original source... Go to PubMed...
    10. Hoekman K, van der Vijgh WJ, Vermorken JB. Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer. Drugs 1999; 57: 133-155. Go to original source... Go to PubMed...
    11. Makridakis NM, Reichardt JK. Multiplex automated primer extension analysis: simultaneous genotyping of several polymorphisms. Biotechniques 2001; 31: 1374-1380. Go to original source... Go to PubMed...
    12. Bodovitz S, Joos T, Bachmann J. Protein biochips: the calm before the storm. Drug Discov Today 2005; 10: 283-287. Go to original source... Go to PubMed...
    13. Ray CA, Bowsher RR, Smith WC et al. Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. J Pharm Biomed Anal 2005; 36: 1037-1044. Go to original source... Go to PubMed...
    14. Li H, Bashir R. On the design and optimization of micro-fluidic dielectrophoretic devices: a dynamic simulation study. Biomed Microdevices 2004; 6: 289-295. Go to original source... Go to PubMed...
    15. Petros WP, Evans WE. Pharmacogenomics in cancer therapy: is host genome variability important? Trends Pharmacol Sci 2004; 25: 457-464. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.